Journal
THERANOSTICS
Volume 11, Issue 13, Pages 6120-6137Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.54881
Keywords
type 1 interferon; immune susceptibility; targeted radionuclide therapy; external beam radiotherapy; checkpoint blockade
Categories
Funding
- University of Wisconsin Carbone Cancer Center (UWCCC)
- NIH [P30 CA014520, P50 DE026787, 1DP5OD024576, U01CA233102, P01CA250972, S10OD 028670-01, T32GM008692, 1K08CA241319, TL1TR002375, F30CA250263]
- Radiological Society of North America [RF1716]
- American Society of Clinical Oncology Hayden Family Foundation Young Investigator Award [12805]
- UW-Madison Radiology MD-PhD Graduate Student Fellowship
- Benston Translational Research Fellowship
- Hillman Early Career Fellowship for Innovative Cancer Research
Ask authors/readers for more resources
This study investigated the time course of STING-dependent IFN1 response following radiation in multiple murine tumor models. The results demonstrated the potential of TRT to stimulate IFN1 activation comparable to that observed with EBRT, which may be critical to the therapeutic integration of TRT with immunotherapies.
Rationale: Clinical interest in combining targeted radionuclide therapies (TRT) with immunotherapies is growing. External beam radiation therapy (EBRT) activates a type 1 interferon (IFN1) response mediated via stimulator of interferon genes (STING), and this is critical to its therapeutic interaction with immune checkpoint blockade. However, little is known about the time course of IFN1 activation after EBRT or whether this may be induced by decay of a TRT source. Methods: We examined the IFN1 response and expression of immune susceptibility markers in B78 and B16 melanomas and MOC2 head and neck cancer murine models using qPCR and western blot. For TRT, we used Y-90 chelated to NM600, an alkylphosphocholine analog that exhibits selective uptake and retention in tumor cells including B78 and MOC2. Results: We observed significant IFN1 activation in all cell lines, with peak activation in B78, B16, and MOC2 cell lines occurring 7, 7, and 1 days, respectively, following RT for all doses. This effect was STING-dependent. Select IFN response genes remained upregulated at 14 days following RT. IFN1 activation following STING agonist treatment in vitro was identical to RT suggesting time course differences between cell lines were mediated by STING pathway kinetics and not DNA damage susceptibility. In vivo delivery of EBRT and TRT to B78 and MOC2 tumors resulted in a comparable time course and magnitude of IFN1 activation. In the MOC2 model, the combination of Y-90-NM600 and dual checkpoint blockade therapy reduced tumor growth and prolonged survival compared to single agent therapy and cumulative dose equivalent combination EBRT and dual checkpoint blockade therapy. Conclusions: We report the time course of the STING-dependent IFN1 response following radiation in multiple murine tumor models. We show the potential of TRT to stimulate IFN1 activation that is comparable to that observed with EBRT and this may be critical to the therapeutic integration of TRT with immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available